James Paul Lang's Insider Trades & SAST Disclosures
James Paul Lang's most recent trade in OptimizeRx Corp was a trade of 321,408 Common Stock done at an average price of $7.6 . Disclosure was reported to the exchange on March 14, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern James Paul Lang.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| OptimizeRx Corp | James Paul Lang | Director | Purchase of securities on an exchange or from another person at price $ 7.60 per share. | 14 Mar 2025 | 321,408 | 389,452 (2%) | 2% | 7.6 | 2,443,761 | Common Stock |
| BioVie Inc | James Paul Lang | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Nov 2024 | 61,600 | 61,600 | - | - | Stock Option (right to buy) | |
| BioVie Inc | James Paul Lang | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Nov 2024 | 22,690 | 22,690 | - | - | Stock Option (right to buy) | |
| OptimizeRx Corp | James Paul Lang | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 13,286 | 68,044 (0%) | 0% | 0 | Common Stock | |
| OptimizeRx Corp | James Paul Lang | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jun 2024 | 10,061 | 54,758 (0%) | 0% | 0 | Common Stock | |
| OptimizeRx Corp | James Paul Lang | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jun 2024 | 10,061 | 0 | - | - | Restricted Stock Units | |
| BioVie Inc | Paul James Lang | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Nov 2023 | 93,500 | 93,500 | - | - | Stock Option (right to buy) | |
| OptimizeRx Corp | James Paul Lang | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2023 | 10,061 | 10,061 | - | - | Restricted Stock Units | |
| OptimizeRx Corp | James Paul Lang | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jun 2023 | 4,637 | 44,697 (0%) | 0% | 0 | Common Stock | |
| OptimizeRx Corp | James Paul Lang | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jun 2023 | 4,637 | 0 | - | - | Restricted Stock Units | |
| OptimizeRx Corp | James Paul Lang | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Mar 2023 | 657 | 40,060 (0%) | 0% | 0 | Common Stock | |
| OptimizeRx Corp | James Paul Lang | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Mar 2023 | 657 | 657 | - | - | Restricted Stock Units | |
| OptimizeRx Corp | James Paul Lang | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Dec 2022 | 409 | 39,403 (0%) | 0% | 0 | Common Stock | |
| OptimizeRx Corp | James Paul Lang | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Dec 2022 | 409 | 0 | - | - | Restricted Stock Units | |
| BioVie Inc | James Paul Lang | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Nov 2022 | 43,578 | 68,622 (1%) | 0% | 0 | COMMON STOCK | |
| OptimizeRx Corp | James Paul Lang | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Sep 2022 | 334 | 38,994 (0%) | 0% | 0 | Common Stock | |
| OptimizeRx Corp | James Paul Lang | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Sep 2022 | 334 | 0 | - | - | Restricted Stock Units | |
| OptimizeRx Corp | James Paul Lang | Director | Purchase of securities on an exchange or from another person at price $ 16.45 per share. | 19 Aug 2022 | 6,000 | 38,660 (0%) | 0% | 16.5 | 98,723 | Common Stock |
| OptimizeRx Corp | James Paul Lang | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 4,637 | 4,637 | - | - | Restricted Stock Units | |
| BioVie Inc | James Paul Lang | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Apr 2022 | 127,900 | 127,900 | - | - | Stock Option (right to buy) | |
| OptimizeRx Corp | James Paul Lang | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Mar 2022 | 657 | 657 | - | - | Restricted Stock Units | |
| OptimizeRx Corp | James Paul Lang | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Sep 2021 | 334 | 334 | - | - | Restricted Stock Units | |
| OptimizeRx Corp | James Paul Lang | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2021 | 407 | 32,660 (0%) | 0% | 0 | Common Stock | |
| OptimizeRx Corp | James Paul Lang | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2021 | 539 | 32,253 (0%) | 0% | 0 | Common Stock | |
| OptimizeRx Corp | James Paul Lang | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2020 | 1,937 | 29,729 (0%) | 0% | 0 | Common Stock | |
| BioVie Inc | James Paul Lang | Director | Grant, award, or other acquisition of securities at price $ 3.50 per share. | 30 Jun 2020 | 1,600 | 25,044 (0%) | 0% | 3.5 | 5,600 | Common Stock |
| BioVie Inc | James Paul Lang | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2020 | 800 | 21,988 | - | - | options | |
| BioVie Inc | James Paul Lang | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2020 | 800 | 21,188 | - | - | options |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges